Rubidium rb-82
Cardiogen, Ruby-fill (rubidium rb-82) is a small molecule pharmaceutical. Rubidium rb-82 was first approved as Cardiogen-82 on 1989-12-29.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Cardiogen, Ruby-fill
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rubidium chloride rb-82
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CARDIOGEN-82 | Bracco Diagnostics | N-019414 RX | 1989-12-29 | 1 products |
| RUBY-FILL | Jubilant Therapeutics | N-202153 RX | 2016-09-30 | 1 products |
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries |
Clinical
Clinical Trials
20 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary artery disease | D003324 | — | I25.1 | — | — | 1 | 2 | 5 | 8 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | 1 | — | — | 1 | 1 | 3 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | 1 | — | 1 |
| Pulmonary arterial hypertension | D000081029 | — | — | — | — | — | 1 | — | 1 |
| Familial primary pulmonary hypertension | D065627 | — | I27.0 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | 1 | — | — | — | 3 | 4 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | 1 | — | — | — | 1 | 2 |
| Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Radiation exposure | D000069079 | — | — | — | — | — | — | 2 | 2 |
| Colorectal neoplasms | D015179 | — | — | — | — | — | — | 1 | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 1 | 1 |
| Head and neck neoplasms | D006258 | — | — | — | — | — | — | 1 | 1 |
| Esophageal neoplasms | D004938 | — | C15 | — | — | — | — | 1 | 1 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | — | — | — | 1 | 1 |
| Myocardial reperfusion | D015425 | — | — | — | — | — | — | 1 | 1 |
| Coronary disease | D003327 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Rubidium rb-82 |
| INN | — |
| Description | Cardiogen, Ruby-fill (rubidium rb-82) is a small molecule pharmaceutical. Rubidium rb-82 was first approved as Cardiogen-82 on 1989-12-29. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | [82Rb] |
Identifiers
| PDB | — |
| CAS-ID | 14391-63-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297424 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 104 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
95 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use